Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.

Fleiss JL, Bigger JT Jr, McDermott M, Miller JP, Moon T, Moss AJ, Oakes D, Rolnitzky LM, Therneau TM.

Circulation. 1990 Feb;81(2):684-5. No abstract available.

PMID:
2297869
2.

Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5). Thrombosis In Myocardial Infarction.

Cannon CP, Sharis PJ, Schweiger MJ, McCabe CH, Diver DJ, Shah PK, Sequeira RF, Greene RM, Perritt RL, Poole WK, Braunwald E.

Am J Cardiol. 1997 Sep 15;80(6):696-9.

PMID:
9315571
6.

Multicenter beta-blocker trials: certainties.

Lubsen J.

Eur Heart J. 1983 Jul;4 Suppl D:147-9.

PMID:
6137375
8.

Effect of acute and long-term beta-adrenergic blockade with alprenolol in definite or suspected myocardial infarction. Study design, patient characteristics and conduct of the study.

Jürgensen HJ, Andersen MP, Bechsgaard P, Frederiksen J, Hansen DA, Nielsen PB, Pedersen F, Pedersen-Bjergaard O, Rasmussen SL.

Acta Med Scand Suppl. 1984;680:8-17. No abstract available.

PMID:
6375283
9.

Clinical trials of platelet-active drugs in coronary heart disease: summary of design features.

Furberg CD, May GS.

Circulation. 1980 Dec;62(6 Pt 2):V49-52.

PMID:
7002352
11.
12.

Early termination of clinical trials with prolonged observation of individual patients: a case study.

van Es GA, Tijssen JG, Lubsen J, van Strik R.

Stat Med. 1987 Dec;6(8):927-37.

PMID:
3438618
13.

Design and methods of the Raloxifene Use for The Heart (RUTH) study.

Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW.

Am J Cardiol. 2001 Aug 15;88(4):392-5.

PMID:
11545760
14.

[Errors of methodology. General considerations seen by the cardiologist].

Orzan F.

G Ital Cardiol. 1985 Jun;15(6):625-7. Italian. No abstract available.

PMID:
4065482
15.

[Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].

Oparil S, Bakir SE.

Drugs. 2000;59 Spec No 2:25-37. Review. French.

PMID:
11002856
17.

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O'Neill W, Todaro TG, Vahanian A, Van de Werf F, Granger CB; APEX-AMI Steering Committee.

Am Heart J. 2005 Mar;149(3):402-7. No abstract available.

PMID:
15864228
18.
20.

A controlled trial of sotalol for 1 year after myocardial infarction.

Julian DG, Jackson FS, Szekely P, Prescott RJ.

Circulation. 1983 Jun;67(6 Pt 2):I61-2.

PMID:
6342842

Supplemental Content

Support Center